Alterity Therapeutics
ATHE
26 hedge funds and large institutions have $2.2M invested in Alterity Therapeutics in 2014 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 7 closing their positions.
71% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $669K
10% less funds holding
Funds holding: 29 → 26 (-3)
34% less capital invested
Capital invested by funds: $3.36M → $2.2M (-$1.16M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$123K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$100K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$54.8K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$30.2K |
| 5 |
Morgan Stanley
New York
|
+$24.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$232K |
| 2 |
AG
Aperio Group
Sausalito,
California
|
-$173K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$167K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$56.8K |
| 5 |
OC
Oppenheimer & Co
New York
|
-$56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OC
26
Oppenheimer & Co
New York
| – | -$56K | -333 | Closed |
|
|
SM
27
Sabby Management
Miami Beach,
Florida
| – | -$48K | -288 | Closed |
|
|
ST
28
Spot Trading
Chicago,
Illinois
| – | -$45K | -270 | Closed |
|
|
WRM
29
Westport Resources Management
Westport,
Connecticut
| – | -$35K | -207 | Closed |
|
|
WAM
30
Wolverine Asset Management
Chicago,
Illinois
| – | -$10K | -65 | Closed |
|
31
Ameriprise
Minneapolis,
Minnesota
| – | -$4.22K | -37 | -95% |
|
ATHE Hedge Fund Activity: Q2 2014 in Review
26 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2014, worth a combined $2.2M — down 34% from $3.36M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATHE and 4 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 6 added.
The largest buyer was Jane Street, adding an estimated $123K. The largest seller was Barclays, exiting entirely with an estimated $232K sold.
- 26 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2014, down from 29 in Q1 2014.
- Funds reported $2.2M of Alterity Therapeutics stock for Q2 2014, down 34% quarter-over-quarter.
- 4 funds opened new Alterity Therapeutics positions in Q2 2014 and 7 closed out, a net change of -3 holders.
- The largest Alterity Therapeutics buyer in Q2 2014 was Jane Street, an estimated $123K added.
- The largest Alterity Therapeutics seller in Q2 2014 was Barclays, an estimated $232K sold.
Based on aggregated 13F filings for Q2 2014.